Bluebird in deal with group representing 100M covered lives, after FDA approval

Following the FDA approval of LYFGENIA on December 8, for sickle cell disease in patients 12 and older with a history of vaso-occlusive events, bluebird bio has signed an outcomes-based agreement with an organization representing approximately 100M covered lives in the U.S. Additionally, the Company is in advanced discussions with a number of the nation’s other large commercial payers and more than 15 Medicaid agencies collectively representing 80% of individuals with sickle cell disease in the U.S. The Company anticipates 85 to 105 patient starts or cell collections, combined across all three of its commercial products:LYFGENIA, ZYNTEGLO, SKYSONA in 2024, Bluebird Bio disclosed in an 8k filing earlier on Thursday.